African trypanosomiasis is lethal if not treated and its incidence is increasing. Existing therapies are antique by contemporary standards and no vaccine is available. The DNA topoisomerases are enzymes essential for nucleic acid biosynthesis and cell survival and are proven targets for clinically valuable anti-infective and antitumor drugs. Previous work from this lab has established that topoisomerase inhibitors cause dramatic lesions in nuclear and mitochondrial (kinetoplast) DNA which are directly proportional to cell killing. This is an ongoing project to examine the DNA topoisomerases as targets for antitrypanosomal drug development, and the specific aims are three. First is to study type I enzymes, including the intracellular localization of structurally unique topo IB.
This aim also includes the newly identified topoisomerases IA, characterizing their gene sequence and investigating intrace!!ular enzyme function by RNAi silencing.
Aim 2 focuses on a previously unrecognized, second type IIA topoisomerase that occurs in trypanosomes: its catalytic features and inhibitor susceptibilities, and the consequences of silencing by RNAi.
The third aim i s to bring these basic molecular studies closer to the clinic by exploring the structure-activity relationship and selective toxicity of known topoisomerase inhibitors against trypanosomes in vitro. Included are recently discovered inhibitors oftopo IB, as well as topo II inhibitors with representatives currently in clinical trials. Compounds that appear most promising will be evaluated in mice. These studies take a multi-faceted, rational, and tangible approach to the development of much-needed new anti-trypanosomal chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI028855-15
Application #
7024470
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Program Officer
Coyne, Philip Edward
Project Start
1990-08-01
Project End
2009-04-30
Budget Start
2006-03-01
Budget End
2009-04-30
Support Year
15
Fiscal Year
2006
Total Cost
$399,144
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Nenortas, Nathaniel P; Cinelli, Maris A; Morrell, Andrew E et al. (2018) Activity of Aromathecins against African Trypanosomes. Antimicrob Agents Chemother 62:
Meyer, Kirsten J; Shapiro, Theresa A (2013) Potent antitrypanosomal activities of heat shock protein 90 inhibitors in vitro and in vivo. J Infect Dis 208:489-99
Roy Chowdhury, Arnab; Bakshi, Rahul; Wang, Jianyang et al. (2010) The killing of African trypanosomes by ethidium bromide. PLoS Pathog 6:e1001226
Tang, Sonya C; Shapiro, Theresa A (2010) Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes. Antimicrob Agents Chemother 54:620-6
Bakshi, Rahul P; Sang, Dongpei; Morrell, Andrew et al. (2009) Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother 53:123-8
Scocca, Jane R; Shapiro, Theresa A (2008) A mitochondrial topoisomerase IA essential for late theta structure resolution in African trypanosomes. Mol Microbiol 67:820-9
Kulikowicz, Tomasz; Shapiro, Theresa A (2006) Distinct genes encode type II Topoisomerases for the nucleus and mitochondrion in the protozoan parasite Trypanosoma brucei. J Biol Chem 281:3048-56
Bakshi, Rahul P; Shapiro, Theresa A (2004) RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 136:249-55
Nenortas, Elizabeth; Kulikowicz, Tomasz; Burri, Christian et al. (2003) Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions. Antimicrob Agents Chemother 47:3015-7
Bodley, Annette L; Chakraborty, Asit K; Xie, Suji et al. (2003) An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci U S A 100:7539-44

Showing the most recent 10 out of 31 publications